{"id":59835,"date":"2026-03-18T13:47:15","date_gmt":"2026-03-18T05:47:15","guid":{"rendered":"https:\/\/flcube.com\/?p=59835"},"modified":"2026-03-18T13:47:15","modified_gmt":"2026-03-18T05:47:15","slug":"simcere-pharma-reports-positive-sim0237-phase-i-ii-data-80-cr-rate-in-bcg-unresponsive-bladder-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59835","title":{"rendered":"Simcere Pharma Reports Positive SIM0237 Phase I\/II Data \u2013 80% CR Rate in BCG\u2011Unresponsive Bladder Cancer"},"content":{"rendered":"\n<p><strong>Simcere Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2096:HKG\">HKG: 2096<\/a>) announced <strong>positive Phase I\/II results<\/strong> for <strong>SIM0237<\/strong>, its <strong>PD\u2011L1\/IL\u201115 bispecific antibody<\/strong>, demonstrating <strong>80% complete response (CR) rate<\/strong> in carcinoma in situ (CIS) patients with <strong>BCG\u2011unresponsive high\u2011risk non\u2011muscle invasive bladder cancer (NMIBC)<\/strong> \u2013 a population with limited therapeutic options following standard intravesical immunotherapy failure.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-data-snapshot\">Clinical Data Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Patient Population<\/th><\/tr><\/thead><tbody><tr><td><strong>Complete Response (CR) Rate<\/strong><\/td><td><strong>80%<\/strong><\/td><td>CIS patients with \u22651 post\u2011baseline tumor assessment (n=evaluable)<\/td><\/tr><tr><td><strong>12\u2011Month Disease\u2011Free Survival (DFS)<\/strong><\/td><td><strong>65.8%<\/strong><\/td><td>Papillary lesion\u2011only patients<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable; no systemic exposure detected<\/td><td>All treated patients (n=49)<\/td><\/tr><tr><td><strong>Administration Route<\/strong><\/td><td>Intravesical (local bladder delivery)<\/td><td>Monotherapy<\/td><\/tr><tr><td><strong>Data Cutoff<\/strong><\/td><td>28\u202fNov\u202f2025<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enrollment:<\/strong> 49 patients received SIM0237 intravesical monotherapy as of cutoff date<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>SIM0237<\/strong> \u2013 <strong>bispecific antibody (BsAb)<\/strong> independently developed by Simcere<\/li>\n\n\n\n<li><strong>Dual Targets:<\/strong><\/li>\n\n\n\n<li><strong>PD\u2011L1<\/strong> \u2013 blocks PD\u20111\/PD\u2011L1 immunosuppressive pathway, relieving T\u2011cell inhibition<\/li>\n\n\n\n<li><strong>IL\u201115<\/strong> \u2013 activates immune system via IL\u201115 signaling, promoting NK and CD8+ T\u2011cell proliferation<\/li>\n\n\n\n<li><strong>Therapeutic Hypothesis:<\/strong> <strong>Dual mechanism<\/strong> combining immunosuppression relief + immune activation for synergistic anti\u2011tumor efficacy<\/li>\n\n\n\n<li><strong>Delivery Advantage:<\/strong> <strong>Intravesical administration<\/strong> \u2013 local bladder delivery with <strong>no systemic exposure<\/strong> detected in serum, minimizing systemic toxicity risk<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-context-amp-unmet-need\">Clinical Context &amp; Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>NMIBC Landscape<\/th><th>SIM0237 Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Standard of Care<\/strong><\/td><td>Intravesical BCG immunotherapy (first\u2011line)<\/td><td>Targets BCG\u2011unresponsive patients \u2013 ~40\u201150% of high\u2011risk NMIBC<\/td><\/tr><tr><td><strong>Post\u2011BCG Options<\/strong><\/td><td>Limited: radical cystectomy (invasive), pembrolizumab (systemic PD\u20111, limited efficacy)<\/td><td>Novel local immunotherapy with dual mechanism; avoids systemic toxicity<\/td><\/tr><tr><td><strong>Clinical Gap<\/strong><\/td><td>No approved intravesical therapy with &gt;50% CR in BCG\u2011unresponsive CIS<\/td><td>80% CR rate exceeds historical benchmarks; cystectomy\u2011sparing potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMIBC Market Dynamics:<\/strong> Global NMIBC therapeutics market estimated at <strong>US$1.2\u20111.5 billion<\/strong> annually; BCG\u2011unresponsive segment (~30,000 new US cases\/year) represents highest\u2011unmet\u2011need subset with limited approved options and significant cystectomy\u2011related morbidity.<\/li>\n\n\n\n<li><strong>SIM0237 Differentiation:<\/strong> Dual PD\u2011L1\/IL\u201115 mechanism distinguishes from single\u2011target intravesical therapies (nadofaragene firadenovec \u2013 gene therapy, limited availability) and systemic pembrolizumab; local delivery with no systemic exposure offers safety profile advantage for elderly\/comorbid patient populations.<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Phase I\/II data supports Phase III pivotal trial design; potential for <strong>Breakthrough Therapy Designation<\/strong> in US and <strong>Conditional Approval Pathway<\/strong> in China given 80% CR rate in validated surrogate endpoint for NMIBC.<\/li>\n\n\n\n<li><strong>Simcere Pipeline Validation:<\/strong> SIM0237 represents lead asset in Simcere&#8217;s bispecific antibody platform; positive bladder cancer data validates PD\u2011L1\/IL\u201115 architecture for potential expansion into other localized malignancies (non\u2011muscle invasive upper tract urothelial carcinoma, colorectal cancer peritoneal metastases).<\/li>\n\n\n\n<li><strong>Commercial Trajectory:<\/strong> Assuming Phase III initiation Q4 2026\u2011Q1 2027 and approval 2029\u20112030, peak sales potential of <strong>US$300\u2011500 million annually<\/strong> in BCG\u2011unresponsive NMIBC with label expansion opportunity in earlier\u2011line bladder cancer maintenance therapy.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial expectations for SIM0237. Actual results may differ due to risks including Phase III trial design challenges, competitive dynamics, and regulatory requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031701271_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026031701271_c.\"><\/object><a id=\"wp-block-file--media-2613c4c8-a13b-4d2e-9579-c37fb6504618\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031701271_c.pdf\">2026031701271_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031701271_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2613c4c8-a13b-4d2e-9579-c37fb6504618\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simcere Pharmaceutical Group Limited (HKG: 2096) announced positive Phase I\/II results for SIM0237, its PD\u2011L1\/IL\u201115&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[1099,271],"class_list":["post-59835","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-hkg-2096","tag-simcere-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simcere Pharma Reports Positive SIM0237 Phase I\/II Data \u2013 80% CR Rate in BCG\u2011Unresponsive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simcere Pharmaceutical Group Limited (HKG: 2096) announced positive Phase I\/II results for SIM0237, its PD\u2011L1\/IL\u201115 bispecific antibody, demonstrating 80% complete response (CR) rate in carcinoma in situ (CIS) patients with BCG\u2011unresponsive high\u2011risk non\u2011muscle invasive bladder cancer (NMIBC) \u2013 a population with limited therapeutic options following standard intravesical immunotherapy failure.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59835\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere Pharma Reports Positive SIM0237 Phase I\/II Data \u2013 80% CR Rate in BCG\u2011Unresponsive Bladder Cancer\" \/>\n<meta property=\"og:description\" content=\"Simcere Pharmaceutical Group Limited (HKG: 2096) announced positive Phase I\/II results for SIM0237, its PD\u2011L1\/IL\u201115 bispecific antibody, demonstrating 80% complete response (CR) rate in carcinoma in situ (CIS) patients with BCG\u2011unresponsive high\u2011risk non\u2011muscle invasive bladder cancer (NMIBC) \u2013 a population with limited therapeutic options following standard intravesical immunotherapy failure.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59835\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T05:47:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59835#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59835\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere Pharma Reports Positive SIM0237 Phase I\\\/II Data \u2013 80% CR Rate in BCG\u2011Unresponsive Bladder Cancer\",\"datePublished\":\"2026-03-18T05:47:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59835\"},\"wordCount\":495,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2096\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59835#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59835\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59835\",\"name\":\"Simcere Pharma Reports Positive SIM0237 Phase I\\\/II Data \u2013 80% CR Rate in BCG\u2011Unresponsive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-18T05:47:15+00:00\",\"description\":\"Simcere Pharmaceutical Group Limited (HKG: 2096) announced positive Phase I\\\/II results for SIM0237, its PD\u2011L1\\\/IL\u201115 bispecific antibody, demonstrating 80% complete response (CR) rate in carcinoma in situ (CIS) patients with BCG\u2011unresponsive high\u2011risk non\u2011muscle invasive bladder cancer (NMIBC) \u2013 a population with limited therapeutic options following standard intravesical immunotherapy failure.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59835#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59835\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59835#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere Pharma Reports Positive SIM0237 Phase I\\\/II Data \u2013 80% CR Rate in BCG\u2011Unresponsive Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere Pharma Reports Positive SIM0237 Phase I\/II Data \u2013 80% CR Rate in BCG\u2011Unresponsive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Simcere Pharmaceutical Group Limited (HKG: 2096) announced positive Phase I\/II results for SIM0237, its PD\u2011L1\/IL\u201115 bispecific antibody, demonstrating 80% complete response (CR) rate in carcinoma in situ (CIS) patients with BCG\u2011unresponsive high\u2011risk non\u2011muscle invasive bladder cancer (NMIBC) \u2013 a population with limited therapeutic options following standard intravesical immunotherapy failure.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59835","og_locale":"en_US","og_type":"article","og_title":"Simcere Pharma Reports Positive SIM0237 Phase I\/II Data \u2013 80% CR Rate in BCG\u2011Unresponsive Bladder Cancer","og_description":"Simcere Pharmaceutical Group Limited (HKG: 2096) announced positive Phase I\/II results for SIM0237, its PD\u2011L1\/IL\u201115 bispecific antibody, demonstrating 80% complete response (CR) rate in carcinoma in situ (CIS) patients with BCG\u2011unresponsive high\u2011risk non\u2011muscle invasive bladder cancer (NMIBC) \u2013 a population with limited therapeutic options following standard intravesical immunotherapy failure.","og_url":"https:\/\/flcube.com\/?p=59835","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-18T05:47:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59835#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59835"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere Pharma Reports Positive SIM0237 Phase I\/II Data \u2013 80% CR Rate in BCG\u2011Unresponsive Bladder Cancer","datePublished":"2026-03-18T05:47:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59835"},"wordCount":495,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2096","Simcere Pharmaceutical"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59835#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59835","url":"https:\/\/flcube.com\/?p=59835","name":"Simcere Pharma Reports Positive SIM0237 Phase I\/II Data \u2013 80% CR Rate in BCG\u2011Unresponsive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-18T05:47:15+00:00","description":"Simcere Pharmaceutical Group Limited (HKG: 2096) announced positive Phase I\/II results for SIM0237, its PD\u2011L1\/IL\u201115 bispecific antibody, demonstrating 80% complete response (CR) rate in carcinoma in situ (CIS) patients with BCG\u2011unresponsive high\u2011risk non\u2011muscle invasive bladder cancer (NMIBC) \u2013 a population with limited therapeutic options following standard intravesical immunotherapy failure.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59835#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59835"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59835#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere Pharma Reports Positive SIM0237 Phase I\/II Data \u2013 80% CR Rate in BCG\u2011Unresponsive Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59835"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59835\/revisions"}],"predecessor-version":[{"id":59838,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59835\/revisions\/59838"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}